Citius Pharmaceuticals, Inc. reported its financial results for the first quarter of fiscal year 2026, ending December 31, 2025, revealing a net revenue of $3.94 million, attributed to the commercial launch of its oncology product, LYMPHIR. This marks a significant milestone for the company, as it had no revenue during the same period in the previous year. The gross profit for the quarter was approximately $3.15 million, reflecting an 80% gross margin on net product revenues. However, the company incurred a net loss of $9.39 million, a slight improvement from the $10.28 million loss reported in the prior year.
Citius Pharmaceuticals experienced a notable decrease in total operating expenses, which rose to $12.17 million from $10.04 million year-over-year. The increase was primarily driven by higher stock-based compensation expenses, which amounted to $4.28 million, compared to $2.52 million in the previous year. Research and development expenses also decreased to $1.60 million from $2.13 million, reflecting reduced costs associated with ongoing clinical trials and product development.
The company’s balance sheet showed total assets of $140.39 million as of December 31, 2025, up from $130.94 million at the end of the previous fiscal year. Cash and cash equivalents increased significantly to $7.72 million, compared to $4.25 million at the end of September 2025. This increase was bolstered by net proceeds of approximately $20.88 million from equity offerings during the quarter. Citius Pharmaceuticals reported a negative working capital of approximately $262,000, indicating ongoing liquidity challenges.
Strategically, Citius has been focused on expanding its product offerings and enhancing its market presence. The company is actively engaged in capital-raising initiatives to support its operations and product development, particularly for its lead candidate, Mino-Lok, which is still awaiting regulatory approval. The company has also entered into various agreements with specialty distributors to facilitate the distribution of LYMPHIR, which is expected to enhance its market penetration.
Looking ahead, Citius Pharmaceuticals anticipates that revenues will continue to grow as LYMPHIR gains acceptance in the oncology market. However, the company acknowledges the need for substantial additional financing to support its operations beyond May 2026, raising concerns about its ability to continue as a going concern. The management is exploring various financing options, including equity and debt financing, to ensure the sustainability of its operations and to meet its financial obligations.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals develops proprietary critical care and dermatological products, including Mino-Lok for catheter infection salvage, Halo-Lido for hemorrhoid relief, and NoveCite stem cell therapy for ARDS. The company focuses on reformulations of approved drugs with strong safety data, targeting large, underserved markets. It leverages regulatory exclusivity, innovative applications, and strategic licensing to provide effective, lower-risk therapeutic solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.